


REMARKS

Applicants respectfully request entry and consideration of the foregoing amendments to the specification and claims to include sequence identifiers. The amendments presented herein add no new matter. Attached hereto is a marked-up version of the changes made to the claims captioned "Version of Amendments With Markings To Show Changes Made."

Respectfully submitted,

Dated: February 4, 2002



John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
(617) 227-7111

Version of Amendments With Markings to Show Changes Made

In the Specification:

Please amend the specification as follows:

At page 12, lines 1-2:

Fig. 1 depicts the nucleic acid sequence of the entire human angiogenin gene including the cDNA sequence as identified by arrows. The nucleic acid sequence of the 5' untranslated region, the open reading frame, and the 3' untranslated region, as well as the polypeptide sequence encoded by the open reading frame, are set forth as (SEQ ID NO:1). The polypeptide sequence encoded by the open reading frame is set forth as (SEQ ID NO:2).

At page 41, lines 1 to 11:

Control sense [S]ODN complementary to JF2S was synthesized and labeled JF1S. Their compositions are:

JF1S 5' - GAAGAGATGGTGATGGGC - 3' (SEQ ID NO: 3)

JF2S 5' - GCCCATCACCATCTCTTC - 3' (SEQ ID NO: 4)

JF4S 5' - ACACGGCATCATGAATCA - 3' (SEQ ID NO: 5)

Other preferred oligonucleotides include the following:

JF6S 5' - CCAGGGGCCCCGCTGGTTA - 3' (SEQ ID NO: 6)

JF8S 5' - ACCAAATTTTATATTCTA - 3' (SEQ ID NO: 7)

JF10S 5' - CAGGCCCATCACCATCAC - 3' (SEQ ID NO: 8)

JF12S 5' - GCCCAGGCCCATCACCAT - 3' (SEQ ID NO: 9)

JF13S 5' - TCTCTGACACGGCATCAT - 3' (SEQ ID NO: 10)

In the Claims:

Please amend the claims as follows:

10. (Amended) The compound of claim 1 wherein the base sequence of the oligonucleotide or analogue thereof is selected from the group consisting of

5' - GCCCATCACCATCTCTTC - 3' (SEQ ID NO: 4),

5' - ACACGGCATCATGAATCA - 3' (SEQ ID NO: 5),

5' - CCAGGGGCCCCGCTGGTTA - 3' (SEQ ID NO: 6),

5' - ACCAAATTTTATATTCTA - 3' (SEQ ID NO: 7),

5' - CAGGCCCATCACCATCAC - 3' (SEQ ID NO: 8),

5' - GCCCAGGCCCATCACCAT - 3' (SEQ ID NO: 9), and

5' - TCTCTGACACGGCATCAT - 3' (SEQ ID NO: 10).

12. (Amended) The compound of claim 11 wherein the base sequence of the oligonucleotide or analogue thereof is selected from the group consisting of

5' - GCCCATCACCATCTCTTC - 3' (SEQ ID NO: 4),

5' - ACACGGCATCATGAATCA - 3' (SEQ ID NO: 5),

5' - CCAGGGGCCCCGCTGGTTA - 3' (SEQ ID NO: 6),

5' - ACCAAATTTTATATTCTA - 3' (SEQ ID NO: 7),

5' - CAGGCCCATCACCATCAC - 3' (SEQ ID NO: 8),

5' - GCCCAGGCCCATCACCAT - 3' (SEQ ID NO: 9), and

5' - TCTCTGACACGGCATCAT - 3' (SEQ ID NO: 10).

14. (Amended) The compound of claim 13 wherein the base sequence is selected from the group consisting of

5' - GCCCATCACCATCTCTTC - 3' (SEQ ID NO: 4),
5' - ACACGGCATCATGAATCA - 3' (SEQ ID NO: 5),
5' - CCAGGGGCCCCGCTGGTTA - 3' (SEQ ID NO: 6),
5' - ACCAAATTTTATATTCTA - 3' (SEQ ID NO: 7),
5' - CAGGCCCATCACCATCAC - 3' (SEQ ID NO: 8),
5' - GCCCAGGCCCATCACCAT - 3' (SEQ ID NO: 9), and
5' - TCTCTGACACGGCATCAT - 3' (SEQ ID NO: 10).